ACE-031
ACE-031 is not a peptide. It is indexed alongside Growth factors and growth hormone-derived compounds because it appears in the same research literature and the same search demand; no statement on this site describes it as a peptide.
Identity
| Field | Value |
|---|---|
| Classification | Not a peptide |
| Primary class | Growth factors and growth hormone-derived compounds |
| CAS registry number | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| PubChem CID | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Molecular weight | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
ACE-031, generic name ramatercept, is a soluble activin type IIB receptor fused to an antibody Fc domain, a fusion protein rather than a peptide; PubChem returned no compound record for the name. A 2013 Muscle and Nerve paper reports a single ascending-dose study in healthy volunteers, and a 2017 paper in the same journal reports a randomised placebo-controlled study in ambulatory boys with Duchenne muscular dystrophy.
A 2026 PLoS One paper reports increased muscle mass and strength in the common marmoset, and a 2025 Drug Testing and Analysis paper reports gel electrophoretic detection of black market material sold under the name, which is the context in which the compound reaches research-chemical catalogues.
[2, 3, 4, 5]Reported mechanism
A soluble activin type IIB receptor described in the retrieved records as a myostatin inhibitor.
[3, 4]Stated in the titles of the cited 2017 Muscle and Nerve and 2026 PLoS One papers.
Targets named in the cited records: myostatin, activin receptor type IIB ligands.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[1]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
ACE-031 appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- ramatercept
- soluble activin type IIB receptor
- ActRIIB-Fc
Where this page sits
Research records
Cited research records for ACE-031, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Follistatin-344 — Growth factors and growth hormone-derived compounds
- Somatropin — Growth factors and growth hormone-derived compounds
Class page: Growth factors and growth hormone-derived compounds. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for ACE-031?
ACE-031, generic name ramatercept, is a soluble activin type IIB receptor fused to an antibody Fc domain, a fusion protein rather than a peptide; PubChem returned no compound record for the name. A 2013 Muscle and Nerve paper reports a single ascending-dose study in healthy volunteers, and a 2017 paper in the same journal reports a randomised placebo-controlled study in ambulatory boys with Duchenne muscular dystrophy.
Which class is ACE-031 indexed under?
ACE-031 is indexed under Growth factors and growth hormone-derived compounds. This class groups the growth factors, growth factor fragments and growth hormone-derived proteins that research-peptide catalogues list alongside the secretagogues, most of which are proteins rather than peptides and are labelled as such on their pages.
What does the FDA application register show for ACE-031?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:ace-031
- A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle & nerve (2013). pmid:23169607
- Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle & nerve (2017). pmid:27462804
- ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus). PloS one (2026). pmid:41686840
- Gel Electrophoretic Detection of Black Market ACE-031. Drug testing and analysis (2025). pmid:40312924
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.